Literature DB >> 27544600

Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice.

Qiong Duan1, Xiaoxiao Mao2, Chaonan Liao3, Haoyang Zhou1, Zelin Sun1, Xu Deng1, Qiuning Hu1, Jun Qi4, Guogang Zhang1, He Huang5, Jorge Plutzky6, Tianlun Yang7.   

Abstract

BACKGROUND: Excessive degradation of extracellular matrix by matrix metalloproteinases (MMP) is the major pathological feature of abdominal aortic aneurysm (AAA). Suppression of extracellular matrix degradation attenuates AAA initiation and progression in preclinical models. In the present study, we wanted to test the effect of JQ1, a small chemical molecule that selectively targets bromodomain and extra-terminal domain (BET), on AngII induced AAA formation in ApoE-/- mice. METHODS AND
RESULTS: To study the role of BET bromodomain in AAA pathogenesis, male ApoE-/- mice were infused with angiotensin II (AngII, 1000ng/kg/min) for 21days and cotreated with JQ1 (50mg/kg daily) or vehicle control (DMSO). In the in vitro study, we determined the mRNA expression of MMP genes by qPCR and their activity both by the kit and gelatin zymography assay. BET bromodomain inhibition resulted in decreased abdominal aortic diameter (P<0.05) measured by in vivo vascular ultrasound and ex vivo pathologic assessment of aortas. In pursuit of mechanisms for this effect on AAA, we observed that JQ1 treatment led to a downregulation of metalloproteinase gene expression and enzymatic activity both in vitro and in vivo.
CONCLUSIONS: BET bromodomain inhibition improved AAA pathological sequelae, and this effect might be achieved though suppression of MMP genes expression and their activity.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aneurysm; BET bromodomain; JQ1; Metalloproteinases

Mesh:

Substances:

Year:  2016        PMID: 27544600     DOI: 10.1016/j.ijcard.2016.08.238

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.

Authors:  Patricia Cristine Borck; Lian-Wang Guo; Jorge Plutzky
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  The BRD4 inhibitor JQ1 protects against chronic obstructive pulmonary disease in mice by suppressing NF-κB activation.

Authors:  Yan Liu; Zhi-Zhen Huang; Li Min; Zhi-Feng Li; Kui Chen
Journal:  Histol Histopathol       Date:  2020-11-20       Impact factor: 2.303

3.  Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells.

Authors:  Sadhan Das; Parijat Senapati; Zhuo Chen; Marpadga A Reddy; Rituparna Ganguly; Linda Lanting; Varun Mandi; Anita Bansal; Amy Leung; Selena Zhang; Ye Jia; Xiwei Wu; Dustin E Schones; Rama Natarajan
Journal:  Nat Commun       Date:  2017-11-13       Impact factor: 17.694

4.  Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.

Authors:  Laura M Tsujikawa; Li Fu; Shovon Das; Christopher Halliday; Brooke D Rakai; Stephanie C Stotz; Christopher D Sarsons; Dean Gilham; Emily Daze; Sylwia Wasiak; Deborah Studer; Kristina D Rinker; Michael Sweeney; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski
Journal:  Clin Epigenetics       Date:  2019-07-12       Impact factor: 6.551

5.  Meta-analysis of the growth rates of abdominal aortic aneurysm in the Chinese population.

Authors:  Tingting Huang; Shuai Liu; Jianhua Huang; Baohui Xu; Yongping Bai; Wei Wang
Journal:  BMC Cardiovasc Disord       Date:  2019-08-22       Impact factor: 2.298

6.  Anti-Diabetic Atherosclerosis by Inhibiting High Glucose-Induced Vascular Smooth Muscle Cell Proliferation via Pin1/BRD4 Pathway.

Authors:  Yuansheng Wu; Meijin Zhang; Changsheng Xu; Dajun Chai; Feng Peng; Jinxiu Lin
Journal:  Oxid Med Cell Longev       Date:  2020-07-23       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.